Details for New Drug Application (NDA): 020597
✉ Email this page to a colleague
The generic ingredient in XALATAN is latanoprost. There are twenty drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.
Summary for 020597
Tradename: | XALATAN |
Applicant: | Upjohn |
Ingredient: | latanoprost |
Patents: | 0 |
Suppliers and Packaging for NDA: 020597
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597 | NDA | PFIZER LABORATORIES DIV PFIZER INC | 0013-8303 | 0013-8303-04 | 1 BOTTLE, DROPPER in 1 CARTON (0013-8303-04) / 2.5 mL in 1 BOTTLE, DROPPER |
XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597 | NDA | Viatris Specialty LLC | 58151-419 | 58151-419-35 | 1 BOTTLE, DROPPER in 1 CARTON (58151-419-35) / 2.5 mL in 1 BOTTLE, DROPPER |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.005% | ||||
Approval Date: | Jun 5, 1996 | TE: | AT | RLD: | Yes |
Expired US Patents for NDA 020597
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | ⤷ Subscribe | ⤷ Subscribe |
Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | ⤷ Subscribe | ⤷ Subscribe |
Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | ⤷ Subscribe | ⤷ Subscribe |
Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | ⤷ Subscribe | ⤷ Subscribe |
Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription